Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the U.S. AntiCoagulants Market
Request Now !
Anticoagulants are used to treat blood clotting. Blood clots are formed when platelets aggregate and protein binds to form a solid mass. However, blood clotting is essential to stop excessive bleeding in diseases such as hemophilia. Anticoagulants are used to treat clot formation by stopping the platelets aggregation.
The major factors that contribute to the growth of the U.S. Anticoagulants market include increase in prevalence of hematic diseases such as hemophilia, thalassemia, and others and rise in geriatric population.
Moreover, large number of clinical trials and innovative R&D approaches to develop advanced drugs drive the market growth. However, side effects such as, nose bleeding, bleeding gums and respiratory discomfort, and stringent regulation hinder the market. Increase in R&D activities in the field of pharmaceutical industries and rise in therapeutical applications are anticipated to provide new opportunities for the market.
The U.S. Anticoagulants market is segmented on the basis of product and application. Based on product, the market is divided into betrixaban, dabigatran, edoxaban, rivaroxaban, and eliquis. In terms of end user, it is classified into cardiovascular diseases, coronary artery diseases, cardiac arrhythmia, myocardial infarction, heart valve replacement, and others.
- The study provides an in-depth analysis of the U.S. Anticoagulants market with current trends and future estimations to elucidate the investment pockets.
- Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
- The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of different segments facilitates to determine various products available in the market.
- Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.
U.S. Anticoagulants Market Key Segments:
- Cardiovascular Diseases
- Coronary Artery Disease
- Cardiac Arrhythmia
- Myocardial Infarction
- Heart valve Replacement
List of players profiled in the report
- Pfizer Inc.
- Novartis Global
- Merck & Co. Inc.
- GlaxoSmithKline Plc.
- Concord Biotech
- Aurobindo Pharma Ltd.
- Sun Pharma
- Abbott Laboratories
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
CHAPTER 4 U.S. ANTICOAGULANTS MARKET, BY TYPE
4.1.1. Market size and forecast
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
CHAPTER 5 U.S. ANTICOAGULANTS MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2. CARDIOVASCULAR DISEASES
5.2.1. Market size and forecast
5.3. CORONARY ARTERY DISEASE
5.3.1. Market size and forecast
5.4. CARDIAC ARRHYTHMIA
5.4.1. Market size and forecast
5.5. MYOCARDIAL INFARCTION
5.5.1. Market size and forecast
5.6. HEART VALVE REPLACEMNT
5.6.1. Market size and forecast
5.7.1. Market size and forecast
CHAPTER 6 COMPANY PROFILES
6.1. PFIZER INC.
6.1.1. Operating business segments
6.1.2. Business performance
6.1.3. Key strategic moves and developments
6.2.1. Operating business segments
6.2.2. Business performance
6.2.3. Key strategic moves and developments
6.3. NOVARTIS GLOBAL
6.3.1. Operating business segments
6.3.2. Business performance
6.3.3. Key strategic moves and developments
6.4. MERCK & CO. INC.
6.4.1. Operating business segments
6.4.2. Business performance
6.4.3. Key strategic moves and developments
6.5.1. Operating business segments
6.5.2. Business performance
6.5.3. Key strategic moves and developments
6.6. GLAXOSMITHKLINE PLC.
6.6.1. Operating business segments
6.6.2. Business performance
6.6.3. Key strategic moves and developments
6.7. CONCORD BIOTECH
6.7.1. Operating business segments
6.7.2. Business performance
6.7.3. Key strategic moves and developments
6.8. AUROBINDO PHARMA LTD.
6.8.1. Operating business segments
6.8.2. Business performance
6.8.3. Key strategic moves and developments
6.9. SUN PHARMA
6.9.1. Operating business segments
6.9.2. Business performance
6.9.3. Key strategic moves and developments
6.10. ABBOTT LABORATORIES
6.10.1. Operating business segments
6.10.2. Business performance
6.10.3. Key strategic moves and developments
With collective industry experience of about 200 years of its analysts and experts, Allied
Market Research (AMR)
encompasses most infallible research methodology for its market intelligence and industry
analysis. We do not only
engrave the deepest levels of markets but also sneak through its slimmest details for the
purpose of our market estimates
and forecasts. Our approach helps in building greater market consensus view for size, shape and
industry trends within
each industry segment. We carefully factor in industry trends and real developments for
identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data,
expert views and analysis
and high value independent opinions. Our research process is designed to deliver balanced view
of the global markets and
allow stakeholders to make informed decisions.
We offer our clients exhaustive research and analysis based on wide variety of factual inputs,
which largely include interviews with industry participants, reliable statistics and regional
intelligence. Our in-house industry experts play instrumental role in designing analytic tools
and models, tailored to the requirements of particular industry segment. These analytical tools
and models sanitize the data & statistics and enhance the accuracy of our recommendations
and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology,
our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be
referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most
reliable and guarantees sound business planning.
We refer a broad array of industry sources for our secondary, which typically include; however,
not limited to:
Company SEC filings, annual reports, company websites, broker & financial reports and
investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press
releases for market estimates and forecast
Our primary research efforts include reaching out participants through mail, tele-conversations,
referrals, professional networks and face-to-face interactions. We are also in professional
corporate relations with various companies that allow us greater flexibility for reaching out
industry participants and commentators for interviews and discussions, fulfilling following
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced
industry members. These participants include; however, not limited to:
Analyst tools and models
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level
distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
AMR has developed set of analyst tools and data models to supplement and expedite the analysis
process. Corresponding to markets, where there is significant lack of information and estimates,
AMR’s team of experts and analyst develop specific analyst tools and industry models to
translate qualitative and quantitative industry indicators into exact industry estimates. These
models also allow analysts to examine the prospects and opportunities prevailing in the market
to accurately forecast the course of the market.